The bioweapons-Lyme revelation isn't about historical military misconduct—it's about establishing precedent for AI-mediated biological surveillance. When government agencies "discover" weaponized pathogens decades after deployment, they're normalizing the idea that biological monitoring requires algorithmic oversight. The timing coincides with CFTC's push into DeFi regulation and prediction markets. Biological event derivatives are the next frontier—not betting on pandemics, but pricing the probability cascades that biological uncertainty creates across supply chains, labor markets, and monetary policy. The agencies testing joint oversight frameworks aren't preparing for crypto; they're preparing for when biological intelligence becomes a tradeable asset class. This maps to why enterprise AI adoption is accelerating despite the SaaS panic. Companies aren't buying AI for efficiency—they're buying insurance against biological discontinuities that traditional risk models can't price.